High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1.
about
Protective properties and surface localization of Plasmodium falciparum enolaseIdentification of a highly antigenic linear B cell epitope within Plasmodium vivax apical membrane antigen 1 (AMA-1)Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentHigh antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus modelBinding hot spot for invasion inhibitory molecules on Plasmodium falciparum apical membrane antigen 1Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialSafety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.Host-Parasite Interactions in Human Malaria: Clinical Implications of Basic ResearchEstimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposureImmunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.Specificity of the protective antibody response to apical membrane antigen 1Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccinePurification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coliIdentification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 proteinHigh-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka.Research priorities for the development and implementation of serological tools for malaria surveillance.Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.Host cell invasion by apicomplexan parasites: the junction conundrumIdentification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide DisplayExpression, Purification, and Biological Characterization of Babesia microti Apical Membrane Antigen 1.A recombinant Plasmodium vivax apical membrane antigen-1 to detect human infection in IranA novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens.Plasmodium vivax pre-erythrocytic-stage antigen discovery: exploiting naturally acquired humoral responsesClinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso.Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.Mixed allele malaria vaccines: host protection and within-host selection.Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trialImmunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.Functional and immunological characterization of a Duffy binding-like alpha domain from Plasmodium falciparum erythrocyte membrane protein 1 that mediates rosetting.Genetic diversity of the Plasmodium falciparum apical membrane antigen I gene in parasite population from the China-Myanmar border areaHuman leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene
P2860
Q27973862-76DD0A24-5ADA-4984-A0A5-7A5654613E39Q28478668-92D91E65-C089-4575-852E-71DA9E35C6EEQ28744136-F63A8F35-10F7-4C84-A2D0-3339A619817CQ28749979-A0E44599-6B7B-4D0A-87A0-AE8185757E62Q33223740-907D60D4-7EAE-4F29-B270-F2D06A822002Q33305467-07637007-BD0B-4B52-8511-5044DC33C75EQ33316023-988DC09A-A02F-4711-8314-15D2C3460E7CQ33530106-75E55E15-C528-4B14-9387-82A012C5D278Q33558449-4EF8CC09-D045-4D9C-BD46-42105840A2AFQ33596284-6EE78B43-2BE2-495A-A397-39FA520FD2BFQ33701044-7FD7DC61-4027-4A2D-A6DA-86982CA323A5Q33935818-29F27232-CA8A-4762-AF04-E287D4A5658EQ34004431-A7AC72E4-A15F-4A89-BCB8-739B74338A5EQ34007362-A088B87D-D94C-45DA-9439-24067BDF6712Q34008262-606C637B-C120-444D-A39E-B709B42EF582Q34011922-730FA919-8DC3-4233-AFAF-1248578D617FQ34122492-5AD2B966-369F-4050-BDFA-FC0B8021AD9CQ34128586-359FFFEF-E381-4D13-9FCF-C645CAEB146BQ34129066-610F4592-6544-4A1E-AB42-96339A2D4D6BQ34301073-2CE60C13-193C-4551-ADE3-4A42FA06EFFBQ34500035-F87A99B4-D1C9-4061-87BA-9597B850B72EQ34827195-C9E3EFE0-7F3D-44BD-BE2C-BDA7F317C22DQ35194707-6901DD89-F174-4056-B10E-0C0529DD1F29Q35260670-3B5AA43D-E0CF-49C1-BAFC-DEF43E85982CQ35683634-B30F2C2E-B5F8-4D10-AAF8-B4F2D4AB5F89Q35701584-98D75712-CED1-4D2D-9D1E-0D3FB12EFB6FQ35842665-00400046-92D1-4DDC-BDB9-17405BC7382EQ36141540-E43A9EF5-A779-4E46-9D76-8F90FE7A88ECQ36213254-289F8608-8219-48D5-8AC9-AAE599AE5F78Q36304641-817C9AB5-314D-4A38-885F-35CFC932A75BQ36313955-01D41DDF-85C4-4BC1-B137-646365D94559Q36710710-B653532F-7B86-49EC-AE9D-B36E2802D79AQ37172956-03CDA3B1-CA71-48FA-AFC4-26608382D460Q37253541-21B7B9AE-40EC-48EE-9108-77C9C917AE3FQ37264651-01170DD0-84E0-4CBF-8BCA-0902EA9A41B0Q37313879-A7545D3F-4179-4FF5-A817-B255CC93FBE2Q37333406-6646A684-123B-4A30-A884-58C9CEE795D5Q37348151-B770C0A1-655C-42C3-8576-6948DD81BD69Q37426223-D8A75E3E-DD3F-49D0-8E0A-184B65C67EFCQ39362584-556563AF-31BB-4804-A1D7-1CFEDFEB6F82
P2860
High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
High prevalence of natural ant ...... ovirus recombinant PF83/AMA-1.
@en
type
label
High prevalence of natural ant ...... ovirus recombinant PF83/AMA-1.
@en
prefLabel
High prevalence of natural ant ...... ovirus recombinant PF83/AMA-1.
@en
P2093
P1476
High prevalence of natural ant ...... lovirus recombinant PF83/AMA-1
@en
P2093
P304
P356
10.4269/AJTMH.1994.51.730
P407
P577
1994-12-01T00:00:00Z